ESA-backed innovation announces FDA clearance and live clinical trials in the UK.

UK-based company Adaptix, who developed a pioneering portable 3D X-ray imaging system with support from ESA’s Business Applications and Space Solutions (BASS) programme and the UK Space Agency, has announced two major milestones: FDA 510(k) clearance for its Adaptix Ortho350 Imaging System and the start of live clinical trials on patients at the Royal Devon University Healthcare NHS Foundation Trust in Exeter.

The Adaptix Ortho350 system delivers high-quality, low-dose 3D imaging for orthopaedic applications. It enables clinicians to obtain a stack of detailed diagnostic slices through the patient with a far higher level of accuracy than 2D X-rays.  Unlike CT scanners it is a portable solution which is particularly beneficial in remote or resource-limited settings, reducing delays and improving access to care.

The recent FDA clearance marks a critical step towards commercial deployment in the United States, validating the system’s safety and effectiveness. Meanwhile, clinical trials in Exeter are assessing its real-world performance, focusing on workflow efficiency and patient outcomes.

“This achievement demonstrates how space-derived technologies can deliver tangible benefits on Earth,” said Arnaud Runge, Technical Officer for ESA on the project. “We are very pleased to have supported this project from the early days and to see it achieve commercial and technical success across multiple markets. The low radiation dose and compactness of the system also mean we could even see Adaptix Ortho350 used in space in the future.”

Dr Paul Bate, CEO of the UK Space Agency said: “This progress shows the impact of collaboration between space and healthcare in driving innovation. By applying techniques originally developed for space, Adaptix is helping clinicians access faster, safer and more accurate diagnostics, directly benefiting patients and improving recovery pathways. We’re proud to have supported this journey through our partnership with ESA and look forward to seeing this technology improve patient outcomes across the UK and beyond.”

Sarah Small, CEO at Adaptix, said: “Securing this FDA 510(k) clearance represents a significant milestone for Adaptix in our mission to transform radiology. We already have a great deal of interest from healthcare providers and clinicians and are looking forward to delivering “3D-First” enhanced orthopaedic DT imaging across Primary Care, Intensive Care and Emergency Departments throughout the US and beyond.”

Adaptix’s imaging technology grew out of methods originally developed for space applications, ensuring compliance with stringent healthcare standards while maintaining portability and cost-effectiveness. It is already in use across the veterinary and non-destructive testing sectors and has also delivered positive results in human cadaver trials. The trial in Exeter is focusing on patients with inflammatory arthritis and will evaluate the performance of the Adaptix 3D imaging technology when compared to traditional 2D X-rays, focusing on three main areas: diagnostic potential, effective measurement of joint space and evaluation of bone density.

“Up to 30% of people with early rheumatoid arthritis are missed when diagnosed using 2D X-rays, but more-detailed 3D imaging – such as MRI and CT scans – is expensive and waiting lists can be long,” said Dr. Siân Phillips, Chief Medical Officer at Adaptix. “The compact design and lower radiation and power requirements of the Adaptix Ortho350 make 3D imaging much more accessible for clinicians and patients alike. These new trials mark an exciting new stage of our journey, not only delivering a clinical assessment of its effectiveness when compared to traditional 2D X-ray modalities, but also proves our range of clinical use cases from diagnostics to assessing disease progression.”

With regulatory approval secured and clinical trials underway, Adaptix is now preparing for commercial rollout in the US, paving the way for a new era of accessible diagnostic imaging worldwide. Looking ahead, CE marking for the system is also in progress, opening the door for commercialisation across Europe in 2026.

Rangelands – mainly consisting of grasslands used by livestock and wildlife to graze and forage - are critical to both food security and climate resilience. They cover some 40% of the Earth’s land surface, providing a third of the world’s biodiversity and a sixth of global food production. But rangelands are rapidly degrading and being lost, while increasing regulations are making grassland management more challenging for farmers. Irish company Proveye has been working with ESA’s Business Applications and Space Solutions (BASS) programme to develop satellite-enabled solutions which are helping to address these challenges.

Proveye has gone from strength to strength, first starting at an ESA Business Incubation Centre (BIC), and then moving on to BASS - first to evaluate market appetite and technical feasibility, and later to establish a commercial solution with the aim of generating  sales and expanding into new markets. 

Their first solution, ProvGrass, an Earth observation-enabled Platform-as-a-Service (PaaS), is designed to help farmers caught between pressures relating to food security on the one hand and increasing sustainability requirements on the other.
Grassland for dairy and beef farming is the biggest forage crop by area globally, as well as being the most challenging to monitor. At the same time, grass quantity and quality management is essential for profitable livestock production but existing solutions only cover a small area, demand much manual labour, have a high capital cost or only provide generalised regional measurements.
The emerging opportunity for ProvGrass is to supply the industry with a solution that enables it to measure, track, encourage and reward the adoption of more sustainable regenerative and productive practises for grassland.

ProvGrass offers:

• integration of satellite and UAV data in one platform for reliable and consistent data.
• quantity and quality metrics to inform the farmer of grass available now and into the future to satisfy the feed demand of the grazing herd
• automated, scalable delivery
• sensor-agnostic methods that make it adaptable to new data and technology of the future

ProvGrass is now attracting significant investments, securing large contracts and generating jobs. It was this first activity that sparked Proveye’s second solution ProvDMR, currently piloting with BASS on several sites in Ireland and Africa. It uses grasslands for above-ground carbon sequestration at scale, while also facilitating biodiversity management in grasslands to support regenerative farming.

Proveye CEO Jerome O’Connell explained: “We started with ProvGrass, and as we were engaging with customers through that, we kept hearing about the challenges of offsetting emissions.”
“Some 40% of Earth’s land surface is grass. We realised there is huge potential around carbon storage and biodiversity offsetting here, with grasslands a virtually untapped natural mechanism to store carbon for nature-based credits.”
“Using satellite imagery to additionally monitor and report on the improvement of biodiversity in grasslands bring greater integrity and higher value than carbon offsets only.” 

The potential for generating nature-based credits from grasslands is currently limited by poor monitoring, reporting and verification capabilities, while existing biodiversity monitoring methods are manual, time-consuming, unreliable and unscalable.

The value added by ProvDMR is related to:

• the almost unlimited spatial coverage provided by ESA’s Sentinel 1 & 2 space assets
• lower operational costs compared to ground-based validation
• scalability from 1ha to global terrestrial land area
• capacity to integrate interpretation options including biomass, fire, stocking density, grazing activity, distribution of nitrogen-fixing vegetation, change in woody biomass, biodiversity, ecosystem health and human activity

Mr O’Connell said: “We have been on a journey with ESA for six years – and are still going. It is fair to say that the funding, support and validation have been fundamental to the business and products that we have developed, and the market penetration that we have been able to achieve. It would have been very difficult to do this without ESA.”

Davide Coppola, Head of Space Application Initiatives Section at BASS, said: “The core aim of BASS is to accelerate the commercialisation of innovative space-based applications and services while also delivering socio-economic impacts at scale. This shared journey with Proveye is a great example of delivering this in practice.”